Healthcare | May 08, 2024
Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia
Investing in Malaysia's largest clinic operator to expand the healthcare business
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
ORACEA is a trademark of Galderma Holdings, S.A.
The project funding will be done through a mix of internal accruals and debts.
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
